Cumming School of Medicine, University of Calgary, Calgary, Alberta.
South Ottawa Medical Centre, Ottawa, Ontario, Canada.
J Am Acad Dermatol. 2020 Jan;82(1):222-228. doi: 10.1016/j.jaad.2019.08.078. Epub 2019 Sep 6.
The cutaneous microbiome has potential for therapeutic intervention in inflammatory-driven skin disease. Research into atopic dermatitis and acne vulgaris has highlighted the importance of the skin microbiota in disease pathogenesis, prognostication, and targets for therapeutic intervention. Current management of these conditions aims to control the inflammatory response thought to be associated with specific pathogens using both topical and systemic antimicrobials. However, commensal microbiota found naturally on the skin have been shown to play an important role in the resolution of disease flares. Although often efficacious, the mainstay treatments are not without adverse effects and raise concerns regarding the development of antimicrobial resistance. Augmentation of microbial communities with targeted biotherapy could revolutionize the way inflammatory conditions of the skin are treated. Herein, we review evidence for the role of the cutaneous microbiome in atopic dermatitis and acne vulgaris and suggest that these conditions highlight the potential for microbiome-directed therapeutics.
皮肤微生物组具有在炎症驱动的皮肤病中进行治疗干预的潜力。对特应性皮炎和寻常痤疮的研究强调了皮肤微生物群在疾病发病机制、预后和治疗靶点中的重要性。目前，这些疾病的治疗旨在通过局部和全身使用抗菌药物来控制与特定病原体相关的炎症反应。然而，在皮肤上自然存在的共生微生物群已被证明在疾病发作的缓解中发挥重要作用。虽然这些方法通常有效，但主要的治疗方法并非没有不良反应，并且人们担心会产生抗微生物药物耐药性。通过靶向生物疗法来增强微生物群落可能会彻底改变皮肤炎症性疾病的治疗方式。在此，我们综述了皮肤微生物组在特应性皮炎和寻常痤疮中的作用的证据，并提出这些疾病突出了微生物组导向治疗的潜力。
